March 3, 2023 – Cue Health, the healthcare technology leader in at-home and point-of-care diagnostic innovations, announced a new collaboration with Pfizer in the U.S. to raise awareness among individuals with certain underlying conditions about the risks of progressing to severe COVID-19 and the importance of seeking treatment if they test positive.
This COVID-19 collaboration with Pfizer builds on recent initiatives launched by Cue to rapidly connect at-risk individuals with providers for care and treatment.
While these educational resources are specific to COVID-19, the Cue platform is designed to support a wide range of diagnostic test-to-treatment areas, and the company plans to make educational resources about treatment and recovery available for other respiratory viruses and sexual health conditions in the future.
An independent study by Mayo Clinic, released in 2021, found Cue’s COVID-19 test showed 97.8% concordance with central lab PCR tests.